Structural basis for the functions of endogenous angiogenesis inhibitors
- PMID: 16869777
- DOI: 10.1101/sqb.2005.70.017
Structural basis for the functions of endogenous angiogenesis inhibitors
Abstract
Tipping the angiogenic balance between pro- and antiangiogenic stimuli to favor vasculature induction and enhanced angiogenesis is a key event in the growth and progression of tumors. Recently, we demonstrated that the genetic loss of normal physiological levels of individual endogenous inhibitors of angiogenesis leads to a change in the balance between proangiogenic stimulators and their inhibitors, thus favoring enhanced angiogensis and increased tumor growth. Therefore, these endogenous angiogenesis inhibitors provide a physiological threshold against the induction of angiogenesis. The antiangiogenic activities of endostatin, tumstatin, and thrombospondin-1 are evaluated and correlated with their three-dimensional structure and active sites, deriving a structural basis for their activities. Collectively, structural analysis of all three inhibitors demonstrates that the active antiangiogenic sites on these molecules are exposed on the surface and available to bind their putative integrin receptors on proliferating endothelial cells.
Similar articles
-
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126. Clin Cancer Res. 2008. PMID: 18316578
-
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.Clin Cancer Res. 2007 Jul 1;13(13):3968-76. doi: 10.1158/1078-0432.CCR-07-0245. Clin Cancer Res. 2007. PMID: 17606731
-
Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8. doi: 10.1016/j.bbrc.2005.05.130. Biochem Biophys Res Commun. 2005. PMID: 15979458 Review.
-
Endogenous inhibitors of angiogenesis.Cancer Res. 2005 May 15;65(10):3967-79. doi: 10.1158/0008-5472.CAN-04-2427. Cancer Res. 2005. PMID: 15899784 Review.
-
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors.Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2934-9. doi: 10.1073/pnas.0500180102. Epub 2005 Feb 14. Proc Natl Acad Sci U S A. 2005. PMID: 15710885 Free PMC article.
Cited by
-
Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities.Cell Mol Life Sci. 2015 Apr;72(8):1537-57. doi: 10.1007/s00018-014-1814-x. Epub 2015 Jan 1. Cell Mol Life Sci. 2015. PMID: 25552244 Free PMC article. Review.
-
Decellularized matrices for cardiovascular tissue engineering.Am J Stem Cells. 2014 Mar 13;3(1):1-20. eCollection 2014. Am J Stem Cells. 2014. PMID: 24660110 Free PMC article. Review.
-
An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo.Peptides. 2011 Sep;32(9):1840-8. doi: 10.1016/j.peptides.2011.08.010. Epub 2011 Aug 16. Peptides. 2011. PMID: 21871510 Free PMC article.
-
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9939-44. doi: 10.1073/pnas.1105041108. Epub 2011 May 27. Proc Natl Acad Sci U S A. 2011. PMID: 21622854 Free PMC article.
-
ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity.Cell Mol Life Sci. 2010 Dec;67(24):4213-32. doi: 10.1007/s00018-010-0431-6. Epub 2010 Jun 24. Cell Mol Life Sci. 2010. PMID: 20574651 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
